The association between psoriasis and increased cancer risk is gaining recognition as studies reveal shared inflammatory and immune pathways. This review examines the relationship between psoriasis and neoplasia, focusing on cancer risk factors in psoriasis patients, the biological pathways underlying this connection, and the impact of various psoriasis treatments on cancer development. Psoriasis patients have a heightened incidence of certain cancers, such as lymphomas, skin cancers, and urological malignancies, potentially linked to immune dysregulation and chronic inflammation. Immunomodulatory treatments for psoriasis, including conventional systemic therapies and biologics, present varied cancer risks, with others, such as phototherapy, associated with an elevated risk of skin cancers. For oncologic patients with psoriasis, management necessitates a tailored approach, balancing effective psoriasis control with minimizing cancer progression risks. The emergence of IL-17 inhibitors, IL-23 inhibitors, and small-molecule therapies offers promising therapeutic alternatives with favorable safety profiles for these patients. This review underscores the need for interdisciplinary collaboration to optimize care for patients managing both psoriasis and malignancy.
随着研究揭示银屑病与癌症风险增加之间存在共同的炎症和免疫通路，两者间的关联日益受到关注。本文综述了银屑病与肿瘤发生的关系，重点探讨银屑病患者的癌症风险因素、潜在生物学通路，以及不同银屑病治疗方法对癌症发展的影响。银屑病患者特定癌症（如淋巴瘤、皮肤癌及泌尿系统恶性肿瘤）的发病率升高，可能与免疫失调和慢性炎症相关。银屑病的免疫调节治疗（包括传统系统治疗和生物制剂）呈现不同的癌症风险，而光疗等其他疗法则与皮肤癌风险升高相关。对于合并肿瘤的银屑病患者，需采取个体化治疗策略，在有效控制银屑病的同时尽可能降低癌症进展风险。IL-17抑制剂、IL-23抑制剂及小分子疗法的出现为这类患者提供了具有良好安全性的治疗新选择。本综述强调，需要通过多学科协作优化银屑病合并恶性肿瘤患者的临床管理。
肿瘤(癌症)患者之家